Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Allison Berger"'
Autor:
Jill Donelan, Stephen Tirrell, Erik Koenig, Bradley Stringer, Kristen Jordan, Cindy Q. Xia, Mark Manfredi, Allison Berger, Yu Yang, Angel Maldonado Lopez, James Garnsey, Nelson Rhodes, Katherine Galvin, Ben Amidon, Paul Hales, Nibedita Chattopadhyay, Hugues Bernard, Bret Bannerman, Greg Hather
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144825 (2015)
PLoS ONE
PLoS ONE
In non-clinical studies, the proteasome inhibitor ixazomib inhibits cell growth in a broad panel of solid tumor cell lines in vitro. In contrast, antitumor activity in xenograft tumors is model-dependent, with some solid tumors showing no response to
Autor:
Hugues Bernard, James J. Garnsey, Erik Koenig, Ben Amidon, Allison Berger, Eric S. Lightcap, Nibedita Chattopadhyay
Publikováno v:
Molecular Cancer Therapeutics. 12:B156-B156
The investigational proteasome inhibitor ixazomib (MLN2238) inhibits cell growth in a broad panel of solid tumor and hematological cell lines when tested in vitro. In contrast, antitumor activity in xenograft-bearing mice is model-dependent, with som
Autor:
N. Chattopadhyay, Paul Hales, Mark Manfredi, J. Garnsey, Allison Berger, E. Koenig, G. Mulligan, Jie Yu, Bret Bannerman, A. DiBacco
Publikováno v:
European Journal of Cancer. 48:69
The investigational drug MLN9708 is a potent, reversible and specific inhibitor of the proteasome. MLN9708 is currently being evaluated in clinical trials of hematologic malignancies (Phase 1, 2, and 3) as well as solid tumors (Phase 1 and 2). Upon e